Actinogen Medical has completed the final patient visit in its pivotal XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with top-line results expected in November. The trial uses the p-tau181 blood biomarker to select patients likely to have Alzheimer’s, aiming to show that Xanamem slows disease progression better than existing antibody treatments. The company targets an effect nearly twice as strong as current drugs and is already planning a larger Phase 3 trial pending positive results. Regulatory discussions with the FDA and EMA confirm one more pivotal trial is needed for marketing approval, with a possibility of accelerated approval if results are strong.
Actinogen Medical's progress in its XanaMIA Phase 2b/3 trial for Alzheimer's disease provides context for health sector trading on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 02, 2026 10:21 WIB: out of 100 priced US health-sector stocks, 18 rose and 81 fell. Notable movers include ABCL at USD 13.96 with a 1-day change of -4.32% and balanced buy/sell activity, NUWE at USD 0.75 up 4.03% but with 97% sell orders, and TGTX at USD 53.62 down 3.87% with all orders to sell.
A $2.03 million short position in Ether (ETH) perpetual futures was liquidated on Binance at 12:30 a.m. ET on October 2, when the price hit $2,747. Short positions profit when prices fall, but liquidation occurs when margin requirements are not met, ...
On October 1, U.S. spot Bitcoin exchange-traded funds (ETFs) attracted $102.7 million in net inflows, reversing the previous day's $148.7 million outflow. BlackRock's iShares Bitcoin Trust led with $195.6 million in inflows, while Grayscale Bitcoin M...
Ether (ETH) experienced $14.24 million in short position liquidations within an hour ending at 8:31 p.m. ET on October 1, as its price increased by 1.02% from $2,718 to $2,746. The total liquidations across Binance, Bybit, and OKX exchanges amounted ...
Aave (AAVE) saw its price rise 4.16% within one hour to $182 on October 2, with a total 24-hour gain of 8.11%. During the same hour, short liquidations across Binance, Bybit, and OKX exchanges reached $350,000, while no long liquidations occurred. Aa...
Kinetiq has closed its kPoints rewards program, allowing points holders to buy 50 million KNTQ tokens at a fixed price of $0.26 each with no lockup, despite the token price dropping over 20% from its recent high. The claim window opened on October 1,...
